Navigation Links
BioSeek Initiates Systems Biology Compound Evaluation Collaboration with UCB
Date:12/5/2007

BURLINGAME, Calif., Dec. 5 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a collaboration agreement with UCB, a global biopharmaceutical leader based in Belgium. Under the collaboration, BioSeek will apply its BioMAP(R) Systems to evaluate a number of UCB compounds across several target classes, in support of target differentiation, lead development, and drug candidate selection activities at UCB.

"We are excited to be working closely with UCB, an innovative biopharmaceutical company combining distinctive strengths in chemistry and biology, and focusing on severe diseases in three important therapeutic areas, CNS, inflammation and oncology," commented Michael C. Venuti, Ph.D., CEO of BioSeek. "This collaboration leverages the power of our systems biology technology across multiple disease areas and multiple phases of the drug development process."

"The BioMAP(R) platform represents a very promising approach to applying the promise of whole-systems biology to the drug discovery and development process," stated Dr. Mark Bushfield, VP, NCE Research, UCB.

BioSeek's BioMAP(R) Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek's database. BioMAP profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications. In addition to characterizing previously identified lead compounds, BioSeek is using BioMAP Systems for primary screening, to rapidly generate lead compounds that have novel activity in a particular disease setting.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to http://www.bioseekinc.com

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 10,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA (Monheim, Germany) is a member of the UCB Group.

BioSeek Contacts:

BioSeek, Inc.

Michael Venuti, Ph.D.

CEO

Tel: 650.552.0754

MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 781.235.3060


'/>"/>
SOURCE BioSeek, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
6. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Harbinger Research Initiates Coverage on HearAtLast
9. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Plano, Texas (PRWEB) , ... February 20, 2017 ... ... vital signs technology, welcomes you to stop by for a visit this week ... IT professionals, clinicians and executives from around the globe. Sensogram will be featured ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and ... at Chuck E. Cheese’s locations throughout New England, New York and New Jersey to ... experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion ... users can easily reveal any logo with a glitch reveal in just a few clicks ... the style and animation of each preset. Use these presets to add a uniquely animated ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to ... other Butler products. Ken was impressed with the safety and reliability of the ... product on his show. This endorsement by Ken Matthews can be heard on ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is ... in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly ... one roof. Smiles by Seese serves patients of all ages with excellence in general, ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017 /PRNewswire/ ... are helping physicians diagnose and treat patients with ... will provide wireless connectivity for ZywiePro, Zywie,s cardiac ... AT&T Control Center . AT&T ... accessible monitoring for those with the disease. The ...
(Date:2/20/2017)... DUBLIN , Feb 20, 2017 ... "Hernia Repair Devices Global Market -Forecast to 2022" report ... ... obesity, the rise in aging population, rising adoption of tension ... are driving the growth of hernia repair devices global market. ...
(Date:2/20/2017)... SAN FRANCISCO , February 20, 2017 /PRNewswire/ ...  is expected to reach USD 58.4 billion by ... View Research, Inc. The market is driven by ... to serve future growth opportunities to the market. ... initiated with an aim of identifying emerging viruses ...
Breaking Medicine Technology: